Sotrovimab – great white hope

European Medicines Agency has started proofing of brand new GlaxoSmithKline´s and Vir Biotechnology´s medication Sotrovimab. However companies´ outcomes are based on laboratory comparisons only, we have decided to use our techniques together with more than one year practice with COVID-19 to discover its merits. Our conclusions are no EBM, but we think it´s worth to take them in mind, first of all the impacts of homocysteine high level and the astonishing ability. Here you are our results

SOTROVIMAB effectivenessBritish
original
British
E484K
Sth.African
B.1.351
Brasil
P.1 a P.2
Indian
“two-ply”
B.1.617
mutation infectiousness twicefourfivefour
Prophylactic effects0 %0 %O %0 %0 %
Medical effects
used following 2 days after infection
hcy 25 – 30,0 mmol90 % 83 %81 %90 % 90 %
hcy 15 – 24,9 mmol95 %89 %89 %95 %96 %
hcy < 15,0 mmol98 %96 %91 %97 %98 %
used following 3 days after infection
hcy 25 – 30,0 mmol76 %35 %46 %48 %76 %
hcy 15 – 24,9 mmol80 %47 %57 %57 %82 %
hcy < 15,0 mmol96 %55 %59 %61 %89 %
used before 5 days after symptoms
hcy 25 – 30,0 mmol36 %16 %13 %18 %54 %
hcy 15 – 24,9 mmol42 %23 %28 %32 %67 %
hcy < 15,0 mmol53 %29 %34 %45 %69 %
used following 5 days after symptoms
hcy 25 – 30,0 mmol5 %4 %2 %4 %27 %
hcy 15 – 24,9 mmol9 %10 %4 %9 %37 %
hcy < 15,0 mmol12 %11 %9 %13 %42 %
Legend:
Hcy – homocysteine level mmol / litr
Source: regenea.eu, not EBM